Health committee  Those negotiations are still under way. I don't know if there is anything at the moment in the contract, but, as I stated publicly, we're making it a high priority to ensure that our vaccine is available to Canadians. Maybe I'll let Paul Hodgson, our director for business develo

Health committee  From my perspective, while intellectual property is certainly important for the commercial manufacturers in making sure their technologies are protected, and while these expert groups with the WHO are confidential in nature, I would also say that in a situation like this, intelle

Health committee  I think you're correct. There are a lot of questions that we simply don't know the answer to at the moment. There are a lot of scientific questions that need to be addressed, such as whether you're susceptible to reinfection or not, if pre-exposure makes you less responsive to va

Health committee  Maybe I can take that question. As part of these expert group meetings that the World Health Organization is organizing weekly—and we're part of that—many of the vaccine manufacturers are actually presenting their data. They're sharing their data publicly. There is willingness t

Health committee  I just want to echo that I think it's very hard to exactly predict right now when this vaccine will be available. As you can imagine, we have people here who are working essentially around the clock to get this done as quickly as possible. I think what we might see, though—and th

Health committee  Good afternoon. Thank you, Mr. Chair. Thank you very much to the committee for giving us the opportunity to address the committee this afternoon. My name is Volker Gerdts. I'm the CEO and director of VIDO-InterVac. I'm joined by Dr. Paul Hodgson, who is our director of busines